Lucid Diagnostics shares surge 10.41% intraday after securing VA contract for EsoGuard esophageal cancer test.

Lucid Diagnostics surged 10.41% intraday after announcing a contract with the U.S. Department of Veterans Affairs (VA) to provide its EsoGuard Esophageal DNA test. The test, now available to 9 million enrolled veterans, targets patients at risk of esophageal cancer and is priced at Medicare rates, ensuring accessibility and revenue stability. The VA contract represents significant market expansion and validates the company’s diagnostic offering, directly driving investor optimism. Other news, including ownership structure and unrelated partnerships (e.g., BioMérieux, PGxAI), did not influence the stock’s intraday movement.